NDRG2 suppresses cell proliferation through down‐regulation of AP‐1 activity in human colon carcinoma cells

Recently, the anti‐tumor activity of N‐myc downstream‐regulated gene 2 (NDRG2) was elucidated, but the molecular mechanism of how NDRG2 works as a tumor suppressor is not well known. To determine the function of NDRG2 as a tumor suppressor, we established stable cell lines expressing NDRG2 protein or its mutant forms, and studied their effects on tumor cell growth. Interestingly, constitutive expression of wild‐type NDRG2 induced the growth retardation of SW620 colon carcinoma cells. Introduction of NDRG2 into SW620 cells induced the decrease of c‐Jun phosphorylation at Ser63, followed by the attenuation of activator protein‐1 (AP‐1) function as a transcriptional activator. Subsequently, the down‐regulation of cyclin D1, which is known as a major target for AP‐1 transcription activator, resulted in cell cycle arrest at G1/S phase. Additionally, treatment of NDRG2‐siRNA on NDRG2‐expressing cells has induced the recovery of c‐Jun phosphorylation and cyclin D1 expression. Cell proliferation of those cells was also increased compared with untreated cells. NDRG2 mutants of which the phosphorylation sites at C‐terminal region were removed by deletion or site‐directed mutagenesis have shown no effect on cyclin D1 expression and could not induce cell growth retardation. In conclusion, NDRG2 modulates intracellular signals to control cell cycle through the regulation of cyclin D1 expression via phosphorylation pathway. © 2008 Wiley‐Liss, Inc.

[1]  P. Brown,et al.  The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors , 2008, Oncogene.

[2]  G. Hoff,et al.  Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma , 2007, BMC Cancer.

[3]  Jian Zhang,et al.  The physical and functional interaction of NDRG2 with MSP58 in cells. , 2007, Biochemical and biophysical research communications.

[4]  J. Herman,et al.  Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1 , 2006, Oncogene.

[5]  Arie Perry,et al.  Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. , 2005, Cancer research.

[6]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Sicinski,et al.  Cell Cycle Progression without Cyclin D-CDK4 and Cyclin D-CDK6 Complexes , 2005, Cell cycle.

[8]  P. Cohen,et al.  Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. , 2004, The Biochemical journal.

[9]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[10]  Yanchun Deng,et al.  NDRG2 expression and mutation in human liver and pancreatic cancers. , 2004, World journal of gastroenterology.

[11]  James M. Roberts,et al.  Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.

[12]  Qiang Shen,et al.  AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity , 2004, Oncogene.

[13]  Hakan Cangul,et al.  Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers , 2004, BMC Genetics.

[14]  L. Augenlicht,et al.  Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice , 2004, Molecular and Cellular Biology.

[15]  K. Akashi,et al.  Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.

[16]  G. Corthals,et al.  Akt Mediates Insulin-stimulated Phosphorylation of Ndrg2 , 2004, Journal of Biological Chemistry.

[17]  Kwang Dong Kim,et al.  Expression and regulation of NDRG2 (N‐myc downstream regulated gene 2) during the differentiation of dendritic cells , 2003, FEBS letters.

[18]  S. Leung,et al.  N‐Myc downstream‐regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation , 2003, International journal of cancer.

[19]  M. Toyoda,et al.  jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. , 2003, Developmental cell.

[20]  R. Hipskind,et al.  Oct-1 Potentiates CREB-Driven Cyclin D1 Promoter Activation via a Phospho-CREB- and CREB Binding Protein-Independent Mechanism , 2002, Molecular and Cellular Biology.

[21]  Toru Suzuki,et al.  Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. , 2002, Genes & development.

[22]  J. Diehl Cycling to Cancer with Cyclin D1 , 2002, Cancer biology & therapy.

[23]  T. Owa,et al.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. , 2001, Current medicinal chemistry.

[24]  Weiya Ma,et al.  Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[26]  T. Miyata,et al.  Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. , 2001, Genomics.

[27]  H. Nishimatsu,et al.  Transcriptional Activation of the cyclin D1 Gene Is Mediated by Multiple Cis-Elements, Including SP1 Sites and a cAMP-responsive Element in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[28]  P K Thomas,et al.  N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. , 2000, American journal of human genetics.

[29]  E. Bossy‐Wetzel,et al.  Cell cycle‐dependent variations in c‐Jun and JunB phosphorylation: a role in the control of cyclin D1 expression , 2000, The EMBO journal.

[30]  W. El-Deiry,et al.  Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.

[31]  N. Colburn,et al.  Activator protein 1 (AP-1)– and nuclear factor κB (NF-κB)–dependent transcriptional events in carcinogenesis , 2000 .

[32]  S. Pomeroy,et al.  A Developmentally Regulated Switch Directs Regenerative Growth of Schwann Cells through Cyclin D1 , 2000, Neuron.

[33]  Chris Albanese,et al.  NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.

[34]  P. Edwards,et al.  Impaired mammary gland development in Cyl-1(-/-) mice during pregnancy and lactation is epithelial cell autonomous. , 1999, Developmental biology.

[35]  T. Commes,et al.  Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating and growth arrested cells. , 1999, Biochimica et biophysica acta.

[36]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Richard J. Lee,et al.  pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. , 1999, The Journal of biological chemistry.

[38]  R. Pestell,et al.  Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Greenberg,et al.  Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1 , 1998, Molecular and Cellular Biology.

[40]  R. Tennant,et al.  Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. , 1998, Genes & development.

[41]  Y. Hosokawa,et al.  Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele‐specific expression , 1998, Genes, chromosomes & cancer.

[42]  Weiya Ma,et al.  Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Weiya Ma,et al.  Inhibition of Activator Protein 1 Activity and Neoplastic Transformation by Aspirin* , 1997, The Journal of Biological Chemistry.

[44]  T. Miyata,et al.  Homocysteine-respondent Genes in Vascular Endothelial Cells Identified by Differential Display Analysis , 1996, The Journal of Biological Chemistry.

[45]  R. Davis,et al.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways , 1996, Journal of Molecular Medicine.

[46]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[47]  G. Stamp,et al.  Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. , 1995, Genes & development.

[48]  S. Elledge,et al.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.

[49]  C. Albanese,et al.  Epidermal Growth Factor and c-Jun Act via a Common DNA Regulatory Element to Stimulate Transcription of the Ovine P-450 Cholesterol Side Chain Cleavage (CYP11A1) Promoter (*) , 1995, The Journal of Biological Chemistry.

[50]  X. Graña,et al.  Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.

[51]  M. Karin The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases (*) , 1995, The Journal of Biological Chemistry.

[52]  Christine E. Canman,et al.  P53, cell cycle control and apoptosis: Implications for cancer , 1995, Cancer and Metastasis Reviews.

[53]  M. Karin,et al.  c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases , 1994, Molecular and cellular biology.

[54]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[55]  M. Beato,et al.  Inducible regulatory elements in the human cyclin D1 promoter. , 1994, Oncogene.

[56]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[57]  R. Weinberg,et al.  Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Karin,et al.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.

[59]  M. Karin,et al.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.

[60]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[61]  Seung-Chul Choi,et al.  A quantitative analysis of N-myc downstream regulated gene 2 (NDRG 2) in human tissues and cell lysates by reverse-phase protein microarray. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[62]  Fuchu He,et al.  Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family , 2004, Molecular and Cellular Biochemistry.

[63]  N. Colburn,et al.  Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. , 2000, Free radical biology & medicine.

[64]  E. Brown,et al.  Inherited and Acquired Disorders of the Extracellular CA2+0-Sensing Receptor , 1998 .

[65]  I. Weinstein Relevance of cyclin D1 and other molecular markers to cancer chemoprevention , 1996, Journal of cellular biochemistry. Supplement.

[66]  Y. Sun,et al.  Redox regulation of transcriptional activators. , 1996, Free radical biology & medicine.

[67]  E. Lees Cyclin dependent kinase regulation. , 1995, Current opinion in cell biology.

[68]  F. C. Lucibello,et al.  Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. , 1994, Oncogene.

[69]  P. Vogt,et al.  jun: oncogene and transcription factor. , 1990, Advances in cancer research.